Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2006

01-03-2006 | Original Article

Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma

Authors: Prof. B. Mihaljevic, MD PhD, R. Nedeljkov-Janćić, V. Ćemerikić-Martinović, D. Babić, M. Čolović

Published in: Medical Oncology | Issue 1/2006

Login to get access
Metadata
Title
Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma
Authors
Prof. B. Mihaljevic, MD PhD
R. Nedeljkov-Janćić
V. Ćemerikić-Martinović
D. Babić
M. Čolović
Publication date
01-03-2006
Publisher
Humana Press
Published in
Medical Oncology / Issue 1/2006
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:23:1:83

Other articles of this Issue 1/2006

Medical Oncology 1/2006 Go to the issue

Original Article

Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy

Review

Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes

Review

T-cell prolymphocytic leukemia

Case Report

Unusual IgD+/CD38-follicular lymphoma with leukemic presentation

Original Article

Epiphora (Excessive tearing) and other ocular manifestations related to weekly docetaxel

Case Report

Peripheral T-cell lymphoma and Job's syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits